Art. -Nr.: HY-16488

Temoporfin

(Synonyms: m-THPC; KW2345)

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 97.34%
CAS. Nr.: 122341-38-2
Formel: C₄₄H₃₂N₄O₄
Molecular Weight:680.75

Speicherung:

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Temoporfin Chemical Structure

CAS. Nr.: 122341-38-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers^[1]^[2]^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	117 nM Compound: m-THPC	Phototoxicity against mouse 4T1 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method Phototoxicity against mouse 4T1 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method	[PMID: 18788727]
4T1	IC₅₀	0.05 μM Compound: Temoporfin	Phototoxicity against mouse 4T1 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay Phototoxicity against mouse 4T1 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay	[PMID: 32916313]
4T1	IC₅₀	38.01 μM Compound: Temoporfin	Dark toxicity in mouse 4T1 cells assessed as reduction in cell viability by MTT assay Dark toxicity in mouse 4T1 cells assessed as reduction in cell viability by MTT assay	[PMID: 32916313]
A549	IC₅₀	0.702 μM Compound: m-THPC	Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 2 J/cm2 measured by MTT assay Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 2 J/cm2 measured by MTT assay	[PMID: 31132530]
A549	IC₅₀	0.779 μM Compound: m-THPC	Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 1 J/cm2 measured by MTT assay Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 1 J/cm2 measured by MTT assay	[PMID: 31132530]
A549	IC₅₀	1.099 μM Compound: m-THPC	Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 0.5 J/cm2 measured by MTT assay Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 0.5 J/cm2 measured by MTT assay	[PMID: 31132530]
A549	CC₅₀	40.7 μM Compound: 40	Cytotoxicity against human A549 cells incubated for 42 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 42 hrs by MTT assay	[PMID: 34458734]
HCT-116	IC₅₀	5.17 ng/mL Compound: temoporfin	Cytotoxicity against human HCT116 cell line Cytotoxicity against human HCT116 cell line	[PMID: 16722648]
HCT-116	IC₅₀	7.6 nM Compound: temoporfin	Cytotoxicity against human HCT116 cell line Cytotoxicity against human HCT116 cell line	[PMID: 16722648]
HCT-116	IC₅₀	40.95 nM Compound: m-THPC, temoporfin	Phototoxicity against human HCT116 cells assessed as nitrite accumulation after 24 hrs irradiated with LED red light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay Phototoxicity against human HCT116 cells assessed as nitrite accumulation after 24 hrs irradiated with LED red light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay	[PMID: 19211252]
HCT-116	IC₅₀	7.6 nM Compound: m-THPC, temoporfin	Phototoxicity against human HCT116 cells after 24 hrs irradiated with tungsten-halogen white light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay Phototoxicity against human HCT116 cells after 24 hrs irradiated with tungsten-halogen white light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay	[PMID: 19211252]
HL-60	IC₅₀	42 nM Compound: m-THPC	Phototoxicity against human HL60 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method Phototoxicity against human HL60 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method	[PMID: 18788727]
HUVEC	IC₅₀	>100 μM Compound: Temoporfin	Dark toxicity in HUVEC assessed as reduction in cell viability by MTT assay Dark toxicity in HUVEC assessed as reduction in cell viability by MTT assay	[PMID: 32916313]
HUVEC	IC₅₀	1.5 μM Compound: Temoporfin	Phototoxicity against HUVEC assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay Phototoxicity against HUVEC assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay	[PMID: 32916313]
MDA-MB-231	IC₅₀	0.87 μM Compound: Temoporfin	Phototoxicity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay Phototoxicity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay	[PMID: 32916313]
MDA-MB-231	IC₅₀	33.42 μM Compound: Temoporfin	Dark toxicity in human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay Dark toxicity in human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay	[PMID: 32916313]

In Vitro

A detailed confocal fluorescence microscopy study of a human adenocarcinoma shows weak localization of Temoporfin in lysosomes and mitochondria. Instead, it is found to be localized in the endoplasmic reticulum (ER) and the Golgi apparatus^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Temoporfin in liver tissue decreases rapidly in time after initial high levels at 4 h after administration (0.1-0.3 mg/kg). In tumour tissue no decrease in photosensitizer levels occurred, with Temoporfin remaining high up to 48 h after administration^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 122341-38-2
Appearance Solid
Molecular Weight 680.75
Formel C₄₄H₃₂N₄O₄
Color Purple to black
SMILES

OC1=CC=CC(/C2=C3CCC(/C(C4=CC(O)=CC=C4)=C5C=C/C(N/5)=C(C6=CC(O)=CC=C6)/C(C=C/7)=NC7=C(C8=CC(O)=CC=C8)/C9=CC=C2N9)=N\3)=C1
Synonyms

m-THPC; KW2345
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (12)

All IF

Sort by:

Journal Impact Factor

Nucleic Acids Res

A new G-quadruplex-specific photosensitizer inducing genome instability in cancer cells by triggering oxidative DNA damage and impeding replication fork progression. [Abstract]

2023 Jul 7;51(12):6264-6285. PMID: 37191066
Theranostics

Targeted Delivery of Functionalized Upconversion Nanoparticles for Externally Triggered Photothermal/Photodynamic Therapies of Brain Glioblastoma. [Abstract]

2018 Feb 4;8(5):1435-1448. PMID: 29507632

Temoporfin purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Feb 4;8(5):1435-1448. [Abstract]

In vivo fluorescence images of glioma-bearing mice intravenously receiving different mTHPC-containing formulations.
Cell Death Dis

Photodynamic therapy induces autophagy-mediated cell death in human colorectal cancer cells via activation of the ROS/JNK signaling pathway. [Abstract]

2020 Oct 31;11(10):938. PMID: 33130826
Pharmaceutics

Temoporfin-Conjugated Upconversion Nanoparticles for NIR-Induced Photodynamic Therapy: Studies with Pancreatic Adenocarcinoma Cells In Vitro and In Vivo. [Abstract]

2023 Nov 28;15(12):2694. PMID: 38140035
Biomacromolecules

Temoporfin-Conjugated PEGylated Poly(N, N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer. [Abstract]

2024 Sep 9;25(9):5771-5785. PMID: 38888278
Cancers (Basel)

Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. [Abstract]

2022 May 31;14(11):2724. PMID: 35681703
Photodiagnosis Photodyn Ther

Assessment of bimodal laser photodynamic therapy at wavelenths of 410 nm and 653 nm for oral precancerous lesions: An in vitro and in vivo study. [Abstract]

2025 Mar 22:104564. PMID: 40127707
Am J Transl Res

Chlorin A-mediated photodynamic therapy induced apoptosis in human cholangiocarcinoma cells via impaired autophagy flux. [Abstract]

2020 Sep 15;12(9):5080-5094. PMID: 33042407
Chemrxiv

2025 Aug 28.
Biomed Pharmacother

Repurposing anti-cancer porphyrin derivative drugs to target SARS-CoV-2 envelope. [Abstract]

2024 May 24:176:116768. PMID: 38795638
SSRN

2023 Jan 26.
Research Square Preprint

2022 Jul.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20.83 mg/mL (30.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4690 mL

7.3448 mL

14.6897 mL

5 mM

0.2938 mL

1.4690 mL

2.9379 mL

10 mM

0.1469 mL

0.7345 mL

1.4690 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (1.47 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (1.47 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Senge MO, et, al. Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer. Photochem Photobiol. 2011 Nov-Dec;87(6):1240-96. [Content Brief]

[2]. Rovers JP, et, al. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model. Br J Cancer. 1999 Oct;81(4):600-8. [Content Brief]

[3]. Reshetov V, et, al. Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo. Int J Nanomedicine. 2013;8:3817-31. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4690 mL	7.3448 mL	14.6897 mL	36.7242 mL
	5 mM	0.2938 mL	1.4690 mL	2.9379 mL	7.3448 mL
	10 mM	0.1469 mL	0.7345 mL	1.4690 mL	3.6724 mL
	15 mM	0.0979 mL	0.4897 mL	0.9793 mL	2.4483 mL
	20 mM	0.0734 mL	0.3672 mL	0.7345 mL	1.8362 mL
	25 mM	0.0588 mL	0.2938 mL	0.5876 mL	1.4690 mL
	30 mM	0.0490 mL	0.2448 mL	0.4897 mL	1.2241 mL

Keywords

Temoporfin

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Temoporfin

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Temoporfin

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Temoporfin

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Temoporfin

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Temoporfin Related Classifications

HY-16488 Related Classifications